CStone breaks up with drugs partner as U.S. rollout stalls
CStone Pharmaceuticals has pulled out of a licensing deal with EQRx for two innovative cancer drugs but holds onto money already received from its partner Key Takeaways: The companies parted…
Recent Articles
RELATED ARTICLES
-
Stock disconnect triggers investor exodus from CStone Pharma
2616.HK -
Akeso marks profit milestone with swift rights issue
9926.HK
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
HBM gets health boost from drug licensing deals
2142.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
